Deal<

 

Hosted by       LSX with strap-3

DEAL OF THE YEAR (<£500M)


This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.

Qualifying criteria
 
- Deal size must be less than £500m
- The lead company must be a European Life Science company
- Open to private or public companies WITH peers, pharma, commercial leaders or big tech
- Deal can be either a licensing deal, single asset acquisition or collaborative agreement involving a particular drug, project or group of drugs/projects
- A license, partnership or alliance between companies NOT M&A
- Deal to have completed in the period between 1 September 2018 and 1 September 2019

Judges will be paying particular attention to:

- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal (upfront, milestone and total value)
- Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next 12-months
- Post-deal performance
 
 
 

2019 WINNER

 

(L-R) Ellie Taylor, Emcee, Ben Owens, Head of Business Development, EUSA Pharma, Lee Morley, CEO, EUSA Pharma and Josh Dance, SVP, LSX Leaders.

 


2019
HIGHLY COMMENDED

 

ALL 2019 FINALISTS

 

Calliditas and Everest Medicines

CALLIDITAS AND EVEREST MEDICINES

Confo Therapeutics and DyNaBind

CONFO THERAPEUTICS AND DYNABIND

Erytech and SQZ Biotechnology

ERYTECH AND SQZ BIOTECHNOLOGY

EUSA Pharma and Janssen

EUSA PHARMA AND JANSSEN

Molecular Partners and Amgen

MOLECULAR PARTNERS AND AMGEN

Oncodesign and Servier

ONCODESIGN AND SERVIER

Oxford Biomedica and Santen

OXFORD BIOMEDICA AND SANTEN

Themis and MSD

THEMIS AND MSD

BUY TICKETS AND TABLES